(Q35637164)

9 August 2017

title

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (English)

1 reference

postmenopausal osteoporosis

9 August 2017

0 references

1 reference

C Cooper

14

0 references

author name string

J-Y Reginster

1

1 reference

9 August 2017

S Adami

2

1 reference

9 August 2017

P Lakatos

3

1 reference

9 August 2017

M Greenwald

4

1 reference

9 August 2017

J J Stepan

5

1 reference

9 August 2017

S L Silverman

6

1 reference

9 August 2017

C Christiansen

7

1 reference

9 August 2017

L Rowell

8

1 reference

9 August 2017

N Mairon

9

1 reference

9 August 2017

B Bonvoisin

10

1 reference

9 August 2017

M K Drezner

11

1 reference

9 August 2017

R Emkey

12

1 reference

9 August 2017

D Felsenberg

13

1 reference

9 August 2017

P D Delmas

15

1 reference

9 August 2017

P D Miller

16

1 reference

9 August 2017

language of work or name

English

0 references

publication date

8 December 2005

1 reference

Annals of the Rheumatic Diseases

9 August 2017

published in

1 reference

9 August 2017

volume

65

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

654-661

1 reference

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Adverse outcomes of osteoporotic fractures in the general population

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

A systematic review of the associations between dose regimens and medication compliance

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Perspective. How many women have osteoporosis?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Ten years' experience with alendronate for osteoporosis in postmenopausal women

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Interventions for helping patients to follow prescriptions for medications

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798147

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

23 October 2018

1 reference

12 December 2020

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

1 reference

12 December 2020

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

12 December 2020

ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2005.044958

1 reference

9 August 2017

1 reference

9 August 2017

1 reference